Compare Fidelity National Information Servcs Inc (FIS) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Illumina, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.3× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Illumina, Inc. for 83 Days on average.
| FIS | ILMN | |
|---|---|---|
Market Cap | $17.71B | $39.95B |
Volume | 9,047,825 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $68.57 | $293.69 |
52-Week Low | $32.44 | $91.00 |
Typical Hold Time | 88 Days | 83 Days |
Enterprise Value | $38.22B | $41.31B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while profitability has improved significantly with net income margin reaching 27.65% in 2026 projections. Recent business developments include multiple core banking platform wins and new product launches, positioning the company for growth in financial technology modernization.
FIS presents a compelling value opportunity with strong analyst support (56.76% buy ratings) and a $47.15 consensus price target representing 37% upside. However, investors face risks from the company's elevated debt levels and inconsistent cash flow generation. The technical bearish signal and recent price weakness suggest potential near-term volatility despite fundamental improvements.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
